Clinical Trial Update: Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the effects of semaglutide in obese youth with prediabetes or new-onset type 2 diabetes and non-alcoholic fatty liver disease; the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Obesity
• Non-alcoholic Fatty Liver Disease
• Prediabetes
• Type 2 Diabetes Mellitus

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: Yale University | Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance | Phase 2 | Status: ACTIVE_NOT_RECRUITING